Down 17%: Is Isis Pharmaceuticals Worth Buying Now?
Despite a deep product pipeline of intriguing RNAi drugs, shares in Isis (ISIS) have toppled this year. Here's what you need to know about Isis and the catalysts likely to move its shares in the coming year.
Today’s Top Biotech Stories: MannKind, GSK, Myriad, and Alnylam
MannKind, GlaxoSmithKline, Myriad Genetics, and Alnylam Pharmaceuticals could all make waves in the biotech sector this morning.